Patient P-01486

Synthetic patientNBL-101 · Day 110 · 25–34 · M · baseline S18Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

51%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S18
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 64 GI symptom burden −29% vs expected — GI Support Protocol GI-04
Day 70 Tolerance state changed — Unstable → Improving
Day 71 ME-01 recommended — Monitoring Escalation ME-01
Day 72 Patient accepted — Started ME-01 in the companion
Day 75 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Nutritional resilience-6
Toxicity+2

What helped?

GI Support Protocol GI-04Day 55
Result: symptom burden −29%
Monitoring Escalation ME-01Day 71
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

55%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

46.6/100

improving · -2.5 vs previous 14 d

Toxicity

Blood

42.8/100

worsening · +4.2 vs previous 14 d

Sleep quality

Wearable

37.8/100

stable · -1.2 vs previous 14 d

Energy level

Daily log

3.8/10

worsening · -0.2 vs previous 14 d

Stress level

Daily log

6.4/10

worsening · +0.4 vs previous 14 d

Steps

Wearable

1,272

improving · +106 vs previous 14 d

Adherence

Companion

52.3 %

worsening · -2.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 36 from the failing basin, 51 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 65%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 65%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 65%

Would not help

Keep fat low
GI +5 next day on high-intake days · n 25
Keep histamine low
GI +4.8 next day on high-intake days · n 18
Keep simple carbs low
GI +3.9 next day on high-intake days · n 21

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+5detractor · 95%
Histamine load
+4.8detractor · 95%
Simple carbohydrates
+3.9detractor · 95%
Spicy / capsaicin
+3detractor · 80%
Alcohol
+1.3no signal · 31%
Insoluble fibre
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 47 and rising
Inflammatory signalling ↑50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 51
Autonomic recovery ↑45
- WearableResting HR 80 bpm
- Wearable1,272 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 43

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 43/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 41 ms
Sleep: 7.3 h
Steps: 1,380
Resting HR: 79 bpm

Daily log: GI score 47, nutritional resilience 47, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01365	57%	S14	SC-12	improved	49
P-01556	56%	S14	GI-04	improved	44
P-01570	55%	S14	SC-12	improved	46
P-01603	55%	S14	GI-04	improved	40
P-01566	54%	S09	GI-04	improved	52
P-01559	53%	S06	GI-04	improved	42
P-01458	52%	S14	GI-04	improved	44
P-01473	52%	S14	GI-04	improved	51
P-01307	51%	S14	GI-04	improved	43
P-01505	51%	S14	NP-02	improved	41
P-01635	50%	S02	GI-04	improved	49
P-01713	50%	S04	GI-04	improved	46